Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls

J Neuroimmunol. 2002 Nov;132(1-2):189-95. doi: 10.1016/s0165-5728(02)00322-3.

Abstract

Administration of beta-receptor agonists alleviate experimental multiple sclerosis (MS) in animal models. In this study, we investigated the effects of terbutaline (5 mg) on IL-10, IL-12, IFN-gamma and TNF-alpha production in whole blood stimulation cultures. IL-10 and IL-12 production were significantly enhanced in controls but not in MS patients (p=0.03 and p=0.001). Effects were not associated with an ongoing immunomodulatory therapy. We conclude that administration of terbutaline induces anti-inflammatory (IL-10) as well as IL-12 protein production in healthy controls but not in MS patients. Our findings might reflect a disturbed autonomic control of the immune system in MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Cytokines / biosynthesis*
  • Female
  • Humans
  • Interferon-gamma / biosynthesis
  • Interleukin-10 / biosynthesis
  • Interleukin-12 / biosynthesis
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology
  • Terbutaline / therapeutic use*
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Cytokines
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Interleukin-12
  • Interferon-gamma
  • Terbutaline